Coagulation Tests and Reversal Agents in Patients Treated with Oral Anticoagulants: The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures
Authors:
- Andrea PozziAPAndrea Pozzi
- Fabiana LucàFLFabiana Lucà
- Sandro GelsominoSGSandro Gelsomino
- Maurizio Giuseppe AbrignaniMAMaurizio Giuseppe Abrignani
- Simona GiubilatoSGSimona Giubilato
- Stefania Angela Di FuscoSFStefania Angela Di Fusco
- Carmelo Massimiliano RaoCRCarmelo Massimiliano Rao
- Stefano CornaraStefano Cornara
- Giorgio CarettaGCGiorgio Caretta
- Roberto CeravoloRCRoberto Ceravolo
- Iris ParriniIPIris Parrini
- Giovanna GeraciGiovanna Geraci
Open Access
- 23 April 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2451
Abstract
In clinical practice, the number of patients treated with direct oral anticoagulants (DOACs) has consistently increased over the years. Since anticoagulant therapy has been associated with an annual incidence of major bleeding (MB) events of approximately 2% to 3.5%, it is of paramount importance to understand how to manage anticoagulated patients with major or life-threatening bleeding. A considerable number of these patients’ conditions necessitate hospitalization, and the administration of reversal agents may be imperative to manage and control bleeding episodes effectively. Importantly, effective strategies for reversing the anticoagulant effects of DOACs have been well recognized. Specifically, idarucizumab has obtained regulatory approval for the reversal of dabigatran, and andexanet alfa has recently been approved for reversing the effects of apixaban or rivaroxaban in patients experiencing life-threatening or uncontrolled bleeding events. Moreover, continuous endeavors are being made to develop supplementary reversal agents. In emergency scenarios where specific reversal agents might not be accessible, non-specific hemostatic agents such as prothrombin complex concentrate can be utilized to neutralize the anticoagulant effects of DOACs. However, it is paramount to emphasize that specific reversal agents, characterized by their efficacy and safety, should be the preferred choice when suitable. Moreover, it is worth noting that adherence to the guidelines for the reversal agents is poor, and there is a notable gap between international recommendations and actual clinical practices in this regard. This narrative review aims to provide physicians with a practical approach to managing specific reversal agents.Keywords
This publication has 104 references indexed in Scilit:
- Seeking a fine balance between effective antithrombotic prophylaxis and safety drug profile in the elderly population: the special case of traumatic brain injuryActa Neurochirurgica, 2023
- The Effects of Oral Anticoagulant Exposure on the Surgical Outcomes of Patients Undergoing Surgery for High-Risk Abdominal EmergenciesJournal of Gastrointestinal Surgery, 2021
- Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and HaemostasisResearch and Practice in Thrombosis and Haemostasis, 2020
- Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital MortalityJAMA, 2018
- Management of Elective Surgery and Emergent Bleeding with Direct Oral AnticoagulantsCurrent Cardiology Reports, 2017
- Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulantsActa Neurochirurgica, 2016
- Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral AnticoagulantsJAMA Neurology, 2016
- Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?Current Cardiology Reports, 2014
- International Epidemiology of Intracerebral HemorrhageCurrent Atherosclerosis Reports, 2012